What Is High-Risk CLL? | Transcript | Chronic Lymphocytic Leukemia | Patient Power


What Is High-Risk CLL?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

Dr. Sharman, what is high-risk CLL, and are there advances for it?

Dr. Sharman:   

I think a lot of the advances are really even more dramatic amongst patients with high-risk CLL. What is high-risk CLL? There's, I wouldn’t say that there's one uniform definition of high-risk CLL for every circumstance, but there are certain things we put into that bucket. Patients with 17P deletion or P53 mutations, that is concerns us that our traditional chemo-immunotherapy approaches aren’t going to be particularly good. They don’t last very long. Short remissions. Patients who relapse very early after a prior chemo-immunotherapy regimen, also a potential high-risk group.

I think now as the field is shifting more towards these targeted agents. We are looking at looking at 17P and its impact on patients treated with ibrutinib (Imbruvica), and it does look like patients with 17P may not get as good a benefit as the patients without 17P. However, they still do better on ibrutinib than anything previously. I think that this is a shifting field right now and what was high-risk just a short while ago may be different than what’s high-risk in the near term. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on June 14, 2019